TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

ELYXYB

CELECOXIB Cyclooxygenase Inhibitors
Immunology Approved 2020-05-05
1
Indication
--
Phase 3 Trials
5
Years on Market

Details

Status
Prescription
First Approved
2020-05-05
Routes
ORAL
Dosage Forms
SOLUTION

Companies

Active Ingredient: CELECOXIB

ELYXYB Approval History

Loading approval history...

What ELYXYB Treats

6 indications

ELYXYB is approved for 6 conditions since its original approval in 2020. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Osteoarthritis
  • Rheumatoid Arthritis
  • Juvenile Rheumatoid Arthritis
  • Ankylosing Spondylitis
  • Acute Pain
  • Primary Dysmenorrhea
Source: FDA Label

ELYXYB Boxed Warning

RISK OF SERIOUS CARDIOVASCULAR AND GASTRO-INTESTINAL EVENTS Cardiovascular Thrombotic Events Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction, and stroke, which can be fatal. This risk may occur early in the treatment and may increase with duration of use [ see Warnings and Precautions (5.1) ]. Celecoxib is contraindicated in the setting of coronary artery bypass graft (CABG) surgery [ see Contraind...

Drugs Similar to ELYXYB

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

CELEBREX
CELECOXIB
6 shared
GD SEARLE LLC
Shared indications:
OsteoarthritisRheumatoid ArthritisJuvenile Rheumatoid Arthritis +3 more
NAPRELAN
NAPROXEN SODIUM
4 shared
TWI PHARMS
Shared indications:
Rheumatoid ArthritisOsteoarthritisAnkylosing Spondylitis +1 more
VYSCOXA
CELECOXIB
4 shared
CARWIN PHARM ASSOC
Shared indications:
OsteoarthritisRheumatoid ArthritisAnkylosing Spondylitis +1 more
COXANTO
OXAPROZIN
3 shared
SOLUBIOMIX
Shared indications:
OsteoarthritisRheumatoid ArthritisJuvenile Rheumatoid Arthritis
DAYPRO
OXAPROZIN
3 shared
Pfizer
Shared indications:
OsteoarthritisRheumatoid ArthritisJuvenile Rheumatoid Arthritis
EC-NAPROSYN
NAPROXEN
3 shared
ATNAHS PHARMA US
Shared indications:
Rheumatoid ArthritisOsteoarthritisAnkylosing Spondylitis
ETODOLAC
ETODOLAC
3 shared
AMNEAL PHARMS CO
Shared indications:
OsteoarthritisRheumatoid ArthritisAcute Pain
NAPROSYN
NAPROXEN
3 shared
ATNAHS PHARMA US
Shared indications:
Rheumatoid ArthritisOsteoarthritisAnkylosing Spondylitis
NAPROXEN AND ESOMEPRAZOLE MAGNESIUM
ESOMEPRAZOLE MAGNESIUM
3 shared
Dr. Reddy's
Shared indications:
OsteoarthritisRheumatoid ArthritisAnkylosing Spondylitis
OXAPROZIN
OXAPROZIN
3 shared
AMNEAL PHARMS CO
Shared indications:
OsteoarthritisRheumatoid ArthritisJuvenile Rheumatoid Arthritis
SULINDAC
SULINDAC
3 shared
WATSON LABS
Shared indications:
OsteoarthritisRheumatoid ArthritisAnkylosing Spondylitis
ABRILADA
ADALIMUMAB-AFZB
2 shared
Pfizer
Shared indications:
Rheumatoid ArthritisAnkylosing Spondylitis
AMJEVITA
ADALIMUMAB-ATTO
2 shared
Amgen
Shared indications:
Rheumatoid ArthritisAnkylosing Spondylitis
ARTHROTEC
DICLOFENAC SODIUM
2 shared
Pfizer
Shared indications:
OsteoarthritisRheumatoid Arthritis
AZULFIDINE EN-TABS
SULFASALAZINE
2 shared
Pfizer
Shared indications:
Rheumatoid ArthritisJuvenile Rheumatoid Arthritis
CATAFLAM
DICLOFENAC POTASSIUM
2 shared
AMICI PHARMA
Shared indications:
OsteoarthritisRheumatoid Arthritis
CIMZIA
CERTOLIZUMAB PEGOL
2 shared
UCB INC
Shared indications:
Rheumatoid ArthritisAnkylosing Spondylitis
CORTEF
HYDROCORTISONE
2 shared
PHARMACIA AND UPJOHN
Shared indications:
Rheumatoid ArthritisAnkylosing Spondylitis
CYLTEZO
ADALIMUMAB-ADBM
2 shared
Boehringer Ingelheim
Shared indications:
Rheumatoid ArthritisAnkylosing Spondylitis
DICLOFENAC POTASSIUM
DICLOFENAC POTASSIUM
2 shared
INGENUS PHARMS LLC
Shared indications:
OsteoarthritisRheumatoid Arthritis
๐Ÿ”ฌ

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
โญ

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
๐Ÿ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

ELYXYB FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

Celecoxib is indicated Celecoxib is a nonsteroidal anti-inflammatory drug indicated for: Osteoarthritis (OA) Rheumatoid Arthritis (RA) Juvenile Rheumatoid Arthritis (JRA) in patients 2 years and older Ankylosing Spondylitis (AS) Acute Pain (AP) Primary Dysmenorrhea (PD) 1.1 Osteoarthritis For the management of the signs and symptoms of OA [ see Clinical Studies ]. 1.2 Rheumatoid Arthritis For the management of the signs and symptoms of RA [ see Clinical Studies ]. 1.3 Juvenile Rheumatoid Arthritis For the management of the signs and symptoms of JRA in patients 2 years and older [ see Clinical ...

โš ๏ธ BOXED WARNING

WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTRO-INTESTINAL EVENTS Cardiovascular Thrombotic Events Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction, and stroke, which can be fatal. This risk may occu...

ELYXYB Patents & Exclusivity

Latest Patent: May 2036

Patents (6 active)

US10722456 Expires May 27, 2036
US10799517 Expires May 27, 2036
US9949990 Expires May 27, 2036
US9795620 Expires May 27, 2036
US9572819 Expires May 27, 2036
US10376527 Expires May 27, 2036
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.